Circulating Tumour Cell Associated MicroRNA Profiles Change during Chemoradiation and Are Predictive of Response in Locally Advanced Rectal Cancer
Authors:
- Stephanie H. LimSLStephanie H. Lim
- Wei ChuaWCWei Chua
- Weng NgWNWeng Ng
- Emilia IpEIEmilia Ip
- Tania M. MarquesTMTania M. Marques
- Nham T. TranNTNham T. Tran
- Margarida Gama-CarvalhoMGMargarida Gama-Carvalho
- Ray AsghariRARay Asghari
- Christopher HendersonCHChristopher Henderson
- Yafeng MaYMYafeng Ma
- Paul de SouzaPSPaul de Souza
- Kevin J. SpringKSKevin J. Spring
Open Access
Abstract
Locally advanced rectal cancer (LARC) has traditionally been treated with trimodality therapy consisting of neoadjuvant radiation +/− chemotherapy, surgery, and adjuvant chemotherapy. There is currently a clinical need for biomarkers to predict treatment response and outcomes, especially during neoadjuvant therapy. Liquid biopsies in the form of circulating tumour cells (CTCs) and circulating nucleic acids in particular microRNAs (miRNA) are novel, the latter also being highly stable and clinically relevant regulators of disease. We studied a prospective cohort of 52 patients with LARC, and obtained samples at baseline, during treatment, and post-treatment. We enumerated CTCs during chemoradiation at these three time-points, using the IsofluxTM (Fluxion Biosciences Inc., Alameda, CA, USA) CTC Isolation and detection platform. We then subjected the isolated CTCs to miRNA expression analyses, using a panel of 106 miRNA candidates. We identified CTCs in 73% of patients at baseline; numbers fell and miRNA expression profiles also changed during treatment. Between baseline and during treatment (week 3) time-points, three microRNAs (hsa-miR-95, hsa-miR-10a, and hsa-miR-16-1*) were highly differentially expressed. Importantly, hsa-miR-19b-3p and hsa-miR-483-5p were found to correlate with good response to treatment. The latter (hsa-miR-483-5p) was also found to be differentially expressed between good responders and poor responders. These miRNAs represent potential predictive biomarkers, and thus a potential miRNA-based treatment strategy. In this study, we demonstrate that CTCs are present and can be isolated in the non-metastatic early-stage cancer setting, and their associated miRNA profiles can potentially be utilized to predict treatment response.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patientsRadiation Oncology, 2012
- Considerations in the development of circulating tumor cell technology for clinical useJournal of Translational Medicine, 2012
- Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay - A comparative studyRadiation Oncology, 2012
- MicroRNA-95 Promotes Cell Proliferation and Targets Sorting Nexin 1 in Human Colorectal CarcinomaCancer Research, 2011
- Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expressionJournal of Gastroenterology and Hepatology, 2010
- HTqPCR: high-throughput analysis and visualization of quantitative real-time PCR data in RBioinformatics, 2009
- Over- and under-expressed microRNAs in human colorectal cancerInternational Journal of Oncology, 2009
- Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screeningGut, 2009
- Pathological response following long‐course neoadjuvant chemoradiotherapy for locally advanced rectal cancerHistopathology, 2005
- Decreased Detection Rate of Disseminated Tumor Cells of Rectal Cancer Patients After Preoperative ChemoradiationAnnals of Surgery, 2003